GO:0048738 cardiac muscle tissue development: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048738 cardiac muscle tissue development describes the biological process by which cardiac muscle tissue is formed, organized, and matured from progenitor cells.
• The process requires coordinated proliferation, differentiation, sarcomere assembly, and electrical coupling of cardiomyocytes [1, 5].
• Key transcription factors such as HAND1, HAND2, NKX2-5, GATA4, MEF2C, and TBX5 drive cardiac lineage commitment and chamber specification.
• MicroRNAs and signaling pathways fine-tune cardiac muscle gene expression during development and disease.
• Loss of cardiac muscle tissue integrity underlies heart failure, myocardial infarction, and cardiomyopathies [4, 8].
• Human iPSC-derived cardiac tissue models and CRISPR editing enable mechanistic studies of cardiac development and regeneration [1, 4, 6].
Description
GO:0048738 cardiac muscle tissue development is a biological process that encompasses the cellular and molecular events leading to the formation of functional cardiac muscle tissue. This process is essential for heart formation during embryogenesis and for the maintenance of cardiac function throughout life [1, 2]. Defects in cardiac muscle tissue development are associated with congenital heart disease and adult-onset cardiomyopathies [2, 4]. Understanding the regulatory networks and structural components of cardiac muscle tissue development is critical for regenerative medicine and disease modeling [1, 4]. This article integrates authoritative GO annotation with published literature to provide a research-grade overview of the genes, mechanisms, and experimental models relevant to GO:0048738 [1, 2, 3].
cardiac muscle tissue development At A Glance
| GO ID | GO:0048738 |
|---|---|
| GO term | cardiac muscle tissue development |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Formation and maturation of cardiac muscle tissue from progenitor cells |
| Key cellular events | Cardiomyocyte differentiation, sarcomere assembly, myofibrillogenesis, electrical coupling |
| Major regulators | HAND1, HAND2, NKX2-5, GATA4, MEF2C, TBX5, microRNAs |
| Associated diseases | Congenital heart disease, cardiomyopathy, heart failure |
| Research models | iPSC-derived cardiomyocytes, engineered heart tissue, CRISPR knockout models |
What Is GO:0048738?
GO:0048738 cardiac muscle tissue development is defined as the biological process whose specific outcome is the progression of cardiac muscle tissue over time, from its formation to the mature structure. This includes the differentiation of cardiac progenitor cells into cardiomyocytes, the assembly of sarcomeres, the organization of myofibrils, and the integration of cells into a functional syncytium [1, 5]. The process is regulated by a core set of cardiac transcription factors and signaling pathways that control gene expression and tissue morphogenesis [2, 3].
Why Is cardiac muscle tissue development Important in Cell Biology?
Cardiac muscle tissue development is fundamental to heart formation and function, and its disruption leads to congenital heart defects and acquired cardiomyopathies [2, 4]. Because adult mammalian cardiomyocytes have limited regenerative capacity, understanding developmental mechanisms is essential for developing regenerative therapies. Moreover, engineered cardiac tissue models that recapitulate developmental processes are valuable for drug screening and disease modeling [1, 5, 6].
• Defects in cardiac muscle tissue development cause congenital heart malformations.
• Impaired cardiac muscle development contributes to cardiomyopathy and heart failure [4, 8].
• Cardiac muscle tissue development is required for establishing the contractile machinery of the heart.
• MicroRNAs regulate gene expression programs during cardiac muscle development.
• Understanding developmental pathways informs strategies for cardiac regeneration.
• Engineered cardiac tissues rely on developmental principles for maturation [1, 6].
• Anisotropic tissue architecture is critical for physiological cardiac function.
• Endothelial-cardiomyocyte interactions modulate cardiac tissue growth.
• Contraction-relaxation coupling is a functional readout of developed cardiac muscle.
• CRISPR-based models enable causal testing of cardiac developmental genes [1, 4].
What Happens During cardiac muscle tissue development?
Cardiac progenitor specification and differentiation
In simple terms: Early embryonic cells are instructed to become heart muscle cells.
Cardiac muscle tissue development begins with the specification of cardiac progenitors from mesoderm, driven by a core network of transcription factors including NKX2-5, GATA4, and TBX5. These factors activate cardiac-specific gene programs and repress non-cardiac lineages. HAND1 and HAND2 are also essential for cardiac development, particularly in chamber specification and morphogenesis. Differentiation into cardiomyocytes involves the expression of sarcomeric proteins and ion channels [1, 5].
Sarcomere assembly and myofibrillogenesis
In simple terms: Heart muscle cells build the molecular motors that enable contraction.
During cardiac muscle tissue development, cardiomyocytes assemble sarcomeres, the basic contractile units composed of actin and myosin filaments, along with accessory proteins. Myofibrillogenesis requires precise stoichiometry of sarcomeric components and is regulated by signaling pathways and mechanical cues [1, 5]. Disruption of sarcomere assembly leads to contractile dysfunction and cardiomyopathy.
Tissue architecture and anisotropy
In simple terms: Heart muscle cells align in a specific direction to generate coordinated contractions.
Cardiac muscle tissue development involves the organization of cardiomyocytes into aligned fibers, a property known as anisotropy, which is essential for efficient force generation. Anisotropic architecture is achieved through cell-cell and cell-matrix interactions, and it influences electrical propagation and mechanical function. Engineered cardiac tissues that mimic native anisotropy show improved maturation and function.
Electrical coupling and functional maturation
In simple terms: Heart muscle cells connect electrically to beat in sync.
As cardiac muscle tissue develops, cardiomyocytes form gap junctions and ion channels that enable electrical coupling and synchronous contraction [1, 8]. Functional maturation includes the development of T-tubules, sarcoplasmic reticulum, and calcium handling machinery. Contraction-relaxation coupling is a hallmark of mature cardiac muscle and is often assessed in engineered tissue models.
Regulation by microRNAs and signaling pathways
In simple terms: Small RNA molecules and signals fine-tune heart muscle development.
MicroRNAs play critical roles in skeletal and cardiac muscle development by post-transcriptionally regulating gene expression. Specific microRNAs modulate cardiomyocyte proliferation, differentiation, and hypertrophy. Signaling pathways such as Notch, Wnt, and BMP also influence cardiac muscle tissue development.
Key Genes Involved in GO:0048738 cardiac muscle tissue development
The following genes are central to cardiac muscle tissue development and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NKX2-5 | Cardiac progenitor specification and differentiation | Mutations linked to congenital heart disease; knockout models |
| GATA4 | Cardiac gene regulation and morphogenesis | Essential for heart tube formation; disease modeling |
| TBX5 | Chamber specification and conduction system | Holt-Oram syndrome; cardiac differentiation studies |
| MEF2C | Cardiomyocyte differentiation and sarcomere assembly | Regulates contractile gene expression |
| HAND1 | Cardiac chamber development and morphogenesis | Knockout causes cardiac defects |
| HAND2 | Cardiac development and outflow tract formation | Critical for right ventricle development |
| MYH7 | Sarcomeric myosin heavy chain | Cardiomyopathy-associated mutations |
| ACTC1 | Sarcomeric actin | Mutations cause hypertrophic cardiomyopathy |
| TNNT2 | Troponin T, sarcomere regulation | Dilated cardiomyopathy models |
| MYBPC3 | Myosin binding protein C | Hypertrophic cardiomyopathy |
| GJA1 | Gap junction protein Connexin 43 | Electrical coupling and arrhythmia |
| SCN5A | Sodium channel | Brugada syndrome and conduction defects |
| CACNA1C | Calcium channel | Long QT syndrome and calcium handling |
| NPPA | Atrial natriuretic peptide | Marker of cardiac hypertrophy |
| MYL2 | Regulatory myosin light chain | Sarcomere assembly and function |
| TNNI3 | Troponin I | Cardiomyopathy and contractile regulation |
| DES | Desmin, intermediate filament | Cytoskeletal integrity in cardiac muscle |
How Is cardiac muscle tissue development Regulated?
Cardiac muscle tissue development is regulated by a combination of transcription factors, microRNAs, and signaling pathways [2, 3]. Core cardiac transcription factors such as NKX2-5, GATA4, TBX5, and MEF2C form a regulatory network that controls downstream sarcomeric and ion channel genes. MicroRNAs modulate the expression of these factors and their targets, influencing cardiomyocyte proliferation and differentiation. Additionally, endothelial-cardiomyocyte interactions and mechanical cues contribute to tissue growth and maturation [7, 6].
cardiac muscle tissue development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NKX2-5 | Congenital heart disease | Knockout iPSC-derived cardiomyocytes |
| MYH7 | Hypertrophic cardiomyopathy | Point mutation knock-in in hiPSCs |
| TNNT2 | Dilated cardiomyopathy | Knock-in of patient mutations |
| GATA4 | Congenital heart defects | CRISPR knockout in cardiac progenitors |
| TBX5 | Holt-Oram syndrome | Knockout and rescue in iPSC-derived cardiomyocytes |
Congenital heart disease
Disruptions in cardiac muscle tissue development are a major cause of congenital heart defects, including septal defects and chamber malformations. Mutations in cardiac transcription factors such as NKX2-5, GATA4, and TBX5 are associated with familial forms of congenital heart disease.
Cardiomyopathy and heart failure
Impaired cardiac muscle tissue development or maintenance contributes to cardiomyopathies, which are characterized by contractile dysfunction and heart failure [4, 8]. Mutations in sarcomeric genes such as MYH7, TNNT2, and MYBPC3 lead to hypertrophic or dilated cardiomyopathy.
Myocardial infarction and regeneration
After myocardial infarction, the loss of cardiac muscle tissue exceeds the limited regenerative capacity of the adult heart, leading to scar formation and heart failure. Understanding developmental mechanisms may inform strategies to regenerate cardiac muscle.
From cardiac muscle tissue development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NKX2-5 impair cardiac differentiation? | CRISPR knockout in hiPSCs |
| Does a MYH7 point mutation cause sarcomere disorganization? | Point mutation knock-in in hiPSCs |
| Can overexpression of MEF2C enhance maturation? | Overexpression in engineered heart tissue |
| Does tagged GATA4 localize to cardiac enhancers? | Tagged knock-in in cardiomyocytes |
| Does HAND2 knockout affect right ventricle formation? | Knockout mouse or hiPSC model |
| Can CRISPR activation of TBX5 rescue conduction defects? | CRISPR activation in iPSC-derived cardiomyocytes |
How to Study the cardiac muscle tissue development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes | Gene expression during differentiation |
| Single-cell RNA-seq | Cell heterogeneity | Cardiac progenitor populations |
| Proteomics | Protein abundance and modifications | Sarcomere assembly |
| Immunofluorescence | Protein localization | Myofibril organization |
| Calcium imaging | Calcium transients | Functional maturation |
| Electrophysiology | Action potentials | Electrical coupling |
| CRISPR screen | Gene essentiality | Discovery of developmental regulators |
Transcriptomic profiling
RNA-seq and single-cell RNA-seq are used to profile gene expression changes during cardiac muscle tissue development and in response to genetic perturbations [1, 2]. These methods identify key transcription factors and signaling pathways.
Proteomic and sarcomere analysis
Proteomics and immunofluorescence can quantify sarcomeric protein expression and organization in developing cardiomyocytes [5, 8]. These approaches reveal defects in myofibrillogenesis and contractile machinery.
Functional assays
Contractility, calcium imaging, and electrophysiology measure functional maturation of cardiac muscle tissue [6, 8]. Engineered heart tissue models allow assessment of force generation and anisotropy.
CRISPR screening
Pooled CRISPR screens can identify genes required for cardiac muscle tissue development and maturation [1, 4]. These screens enable unbiased discovery of regulators and disease modifiers.
How CRISPR Can Be Used to Study GO:0048738 cardiac muscle tissue development
Knockout
CRISPR knockout of cardiac genes such as NKX2-5 or GATA4 in hiPSCs or animal models can reveal their essential roles in cardiac muscle tissue development. Knockout models help determine whether a gene is required for differentiation, sarcomere assembly, or electrical coupling.
Point Mutation
Point mutations identified in patients with cardiomyopathy or congenital heart disease can be introduced into hiPSCs using CRISPR to model disease mechanisms [4, 8]. These models allow assessment of sarcomere function and contractility.
Knock-in
Knock-in of fluorescent tags or reporter genes into cardiac loci enables live imaging of cardiac muscle tissue development. Tagged knock-in models are useful for tracking sarcomeric proteins and transcription factor localization.
Overexpression
CRISPR activation or cDNA overexpression can be used to test whether increased expression of a cardiac gene enhances maturation or regeneration. Overexpression of microRNAs or transcription factors may promote cardiac muscle tissue development.
How EDITGENE Supports cardiac muscle tissue development Research
Researchers studying cardiac muscle tissue development-related genes often need to determine whether a candidate gene is causally involved in cardiomyocyte differentiation, sarcomere assembly, or tissue maturation. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for cardiac muscle tissue development research.
Frequently Asked Questions About cardiac muscle tissue development
What is GO:0048738 cardiac muscle tissue development?
GO:0048738 is a Gene Ontology biological process term describing the formation and maturation of cardiac muscle tissue from progenitor cells.
What genes are involved in cardiac muscle tissue development?
Key genes include NKX2-5, GATA4, TBX5, MEF2C, HAND1, HAND2, and sarcomeric genes such as MYH7 and TNNT2 [2, 5].
How is cardiac muscle tissue development regulated?
It is regulated by transcription factors, microRNAs, and signaling pathways that control cardiomyocyte differentiation and maturation [2, 3].
What diseases are associated with defects in cardiac muscle tissue development?
Congenital heart disease, cardiomyopathy, and heart failure are associated with disrupted cardiac muscle tissue development [2, 4, 8].
What model systems are used to study cardiac muscle tissue development?
Human iPSC-derived cardiomyocytes, engineered heart tissue, and CRISPR-edited animal models are commonly used [1, 4, 6].
How can CRISPR be used to study cardiac muscle tissue development?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of cardiac genes [1, 4].
What is the role of microRNAs in cardiac muscle development?
MicroRNAs post-transcriptionally regulate gene expression programs during cardiac muscle development.
Why is anisotropy important in cardiac muscle tissue?
Anisotropy aligns cardiomyocytes for efficient force generation and electrical propagation.
What methods measure cardiac muscle tissue development?
RNA-seq, proteomics, calcium imaging, electrophysiology, and contractility assays are used [1, 5, 6, 8].
How does EDITGENE support cardiac muscle tissue development research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services [1, 2, 4].
Conclusion
GO:0048738 cardiac muscle tissue development is a fundamental biological process that integrates transcriptional networks, sarcomere assembly, and tissue architecture to build a functional heart [1, 2, 5]. Disruptions in this process lead to congenital heart disease and cardiomyopathy, making it a key area for regenerative medicine and drug discovery [4, 8]. CRISPR-based models and engineered tissue platforms are powerful tools to dissect the mechanisms of cardiac muscle tissue development and to test therapeutic strategies [1, 4, 6].
References
- 1. Weinberger F et al.. 2017. Engineering Cardiac Muscle Tissue: A Maturating Field of Research.. Circ Res 120(9):1487-1500 PMID: 28450366
- 2. George RM et al.. 2019. Hand Factors in Cardiac Development.. Anat Rec (Hoboken) 302(1):101-107 PMID: 30288953
- 3. Callis TE et al.. 2007. MicroRNAs in skeletal and cardiac muscle development.. DNA Cell Biol 26(4):219-25 PMID: 17465888
- 4. Laflamme MA et al.. 2011. Heart regeneration.. Nature 473(7347):326-35 PMID: 21593865
- 5. Zimmermann WH et al.. 2002. Tissue engineering of a differentiated cardiac muscle construct.. Circ Res 90(2):223-30 PMID: 11834716
- 6. Jain A et al.. 2024. Essential Role of Anisotropy in Bioengineered Cardiac Tissue Models.. Adv Biol (Weinh) 8(3):e2300197 PMID: 38126909
- 7. Balligand JL et al.. 1997. Cardiac endothelium and tissue growth.. Prog Cardiovasc Dis 39(4):351-60 PMID: 9050820
- 8. Janssen PM. 2010. Myocardial contraction-relaxation coupling.. Am J Physiol Heart Circ Physiol 299(6):H1741-9 PMID: 20852049
